6-Ethoxy-1H-indazole-3-carboxaldehyde | 1056169-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 6-Ethoxy-1H-indazole-3-carboxaldehyde
• 英文别名: 6-ethoxy-2H-indazole-3-carbaldehyde
• CAS: 1056169-34-6
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.2
• InChiKey: XLYFPQOWGVCCJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Indazole benzimidazole compounds
  申请人：Chiron Corporation

  公开号：US20030207883A1

  公开（公告）日：2003-11-06

  Organic compounds having the structure I are provided where the variables have the values described herein. 1 Pharmaceutical formulations and medicaments include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compound or a pharmaceutically acceptable salt of the organic compound with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation or medicament according to the invention to a patient in need thereof.

  提供具有结构I的有机化合物，其中变量具有所述的值。1药物制剂和药物包括该有机化合物或其药学上可接受的盐和药学上可接受的载体，并可通过将该有机化合物或其药学上可接受的盐与载体和水混合制备。治疗患者的方法包括向需要该药物的患者施用本发明的药物制剂或药物。
• INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS
  申请人：CHIRON CORPORATION

  公开号：EP1401831A1

  公开（公告）日：2004-03-31
• US7064215B2
  申请人：——

  公开号：US7064215B2

  公开（公告）日：2006-06-20
• US7642278B2
  申请人：——

  公开号：US7642278B2

  公开（公告）日：2010-01-05
• [EN] INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS<br/>[FR] COMPOSES D'INDAZOLE BENZIMIDAZOLE UTILISES COMME INHIBITEURS DE TYROSINE ET DE SERINE/THREONINE KINASE
  申请人：CHIRON CORP

  公开号：WO2003004488A1

  公开（公告）日：2003-01-16

  Organic compounds having the structure I are provided where the variables have the values described herein. Pharmaceutical formulations and medicaments include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compound or a pharmaceutically acceptable salt of the organic compound with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation or medicament according to the invention to a patient in need thereof.